// App-Quantinova.ai

P186 : Outcomes of maintenance ustekinumab therapy for Crohn’s disease based on inflammatory burden: A post-hoc analysis of the UNITI trials

Researchers

Presenter

  • S Ghosh

Principal Investigators

  • B Sattin

  • V Tornatore

  • C Gasink

  • L -L Gao

  • S Sloan

  • P Rutgeerts

  • B Sands

  • S Hanauer

  • B Feagan

Medical Centers

  • University of Birmingham, Birmingham, United Kingdom

  • Janssen Inc., Toronto, ON, Canada

  • Janssen-Cilag SpA,Cologno Monzese,Italy

  • Janssen Scientific Affairs, Horsham, PA

  • University Hospital Gasthuisberg, Division of Gastroenterology, Leuven, Belgium

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Northwestern University, Feinberg School of Medicine, Chicago, IL

  • University of Western Ontario, Robarts Research Institute, London, ON, Canada

Locations

  • United Kingdom

  • Canada

  • Italy

  • United States

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • C reactive protein

Drug/Treatment

  • Ustekinumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved